Souhaitez-vous accéder aux communiqués récents ?

MONTRÉAL, 02 avr. 2025 (GLOBE NEWSWIRE) -- La Fondation du Centre universitaire de santé McGill (CUSM) est fière d’annoncer que son ambitieuse campagne Oser rêver a dépassé son objectif de...

MONTREAL, April 02, 2025 (GLOBE NEWSWIRE) -- The McGill University Health Centre (MUHC) Foundation is proud to announce the successful completion of its ambitious Dream Big campaign, which has...

Financing led by new investor Bain Capital with participation from new investor Wellington Management and all existing investors Proceeds to support advancement of ATSN-201 through potential approval...

Continued Clear Visual Evidence of Almost Completely Healed Skin After 6 weeks TreatmentHigh Durability of Treatment Effect of QRX003 with Continuous Daily Dosing Patient Continues Not to Require...

BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that...

The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 program Nurix DEL-AI drug discovery engine generated a drug discovery program to...

NEWTON, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble...

Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California

Delhi, April 02, 2025 (GLOBE NEWSWIRE) -- Global Natural Killer (NK) Cell Therapy Clinical Trials, Proprietary Technologies, Collaborations and Market Opportunity Insight 2025 Report Highlights...

Delhi, April 02, 2025 (GLOBE NEWSWIRE) -- Global VISTA Inhibitor Clinical Trials, Drug Development Opportunities & Patent Insight 2025 Report Highlights & Findings: First VISTA...